cyrilzakka/clinical-trials huggingface dataset:
Metabiomics Colon Cancer Clinical Research Study

The specific aim of the study is to determine the false negative rate of the Metabiomics Colon Polyp and Colorectal Cancer Assay for Cancer.

The purpose of this study is to conduct clinical research to investigate the association of the gut microbiome with colonic neoplasia. In this case several types of gut microbiome samples will be collected from patients undergoing colectomy for colonic adenocarcinoma; those samples will be tested by Metabiomics Colon Polyp and Colorectal Cancer Assay and the percentage of false negative (test returns a negative for cancer) results determined.

Eligibility Criteria:
Inclusion Criteria:

* Recently diagnosed with colorectal cancer (CRC) and scheduled for colectomy
* Male or female,
* Age: 18-95 years,
* Able to comprehend, sign, and date the written informed consent form (ICF),
* Able to give informed consent in English
* Women and minorities will be included.

Exclusion Criteria:

* History of Inflammatory Bowel Disease
* Antibiotics within 2 weeks of sample collection.
* Colonoscopy, colon prep or bowel contrast agent within 7 days prior to sample collection
* Any radiation therapy
Applying Herrmann's Brain Quadrant Model to Learning Styles in Anesthesiology Residents

the ability to learn and adapt to clinical demands is essential in the training of residents. The Herrmann Brain Model categorizes thinking styles based on the preference for utilizing brain quadrants, serving as an applied tool for residents to assess their learning preferences.

This study delineates the learning styles according to Herrmann's brain quadrant model among anesthesiology residents at the National Western Specialty Hospital, Mexican Social Security Institute. Cross-sectional descriptive study; the Herrmann Brain Dominance Test was administered to anesthesiology residents. Each brain quadrant embodies distinct characteristics, thinking patterns, and approaches to knowledge acquisition. The test comprises 120 multiple-choice items on academic, daily, and professional scenarios. The quadrants are described as follows: LC "Scientific Expert," LL "Organizer-Introvert," RC "Interpersonal Strategist," RL "Imaginative Communicator."

Eligibility Criteria:
Inclusion Criteria:

* Anesthesiology residents of the National Western Specialty Hospital, Mexican Social Security Institute

Exclusion Criteria:

* Residents of other specialties of the National Western Specialty Hospital, Mexican Social Security Institute
Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers

The purpose of this study is to determine the effect of nocturnal administration of Anti-hypertensive medications in Non-dippers.

Efficacy variables.

1. ECHO
2. 24hr. horter
3. IMT
4. BUN/crea, urine analysis (microalbulinuria
5. Cardio vascular event. "


Eligibility Criteria:
Inclusion Criteria:

1. Essential hypertension (stage 1-2)
2. 24hr. holer : non-dipper
3. Age 18 \~70.

Exclusion Criteria:

1. Any known malignant disease
2. Renal failure , creatinine \>2.0mg/dl
3. Liver disease
EXErcise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Treatment for Cancer

This protocol seeks to analyze patient outcomes of the standard of care, monitored group exercise regimen of high-load resistance training and functional exercises with compound movements under close supervision on individuals who have been treated for cancer.


Eligibility Criteria:
Inclusion Criteria:

1. Age 20-89 years
2. Women of child-bearing potential must verbally confirm lack of pregnancy prior to enrollment. They should also consent to use adequate contraception during the course of the study.
3. Participants must be determined capable of engaging in resistance training by exercise personnel and/or study PI
4. Participants must complete an assessment by EOC staff and be determined safe to engage in the workout regimen by the study exercise personnel.
5. Individuals not deemed safe to participate in the standard EOC exercise program will be referred to physical therapy or elsewhere

Exclusion Criteria:

1. Severe arthritic, joint, cardiovascular, or musculoskeletal condition that would interfere with exercise program
Effect of Motor Imaginary Training on Upper Limb Functions in Stroke

This study will provide knowledge about effectiveness of motor imaginary training in upper limb performance in chronic stroke patients. Very little data is available about the use in Motor Imaginary in post stroke upper limb rehabilitation in Pakistan. Moreover, studies done previously did not specified population of stroke; This study will include MCA stroke patients only, whom upper limb weakness is more prevalent.

Motor imagery is a technique for inducing motor activity in response to a certain motor output by producing a mental image of the action without intending to conduct it. It is a cognitive technique that, rather than making a patient to pick up new procedures, promotes neural alterations in order enable the patient to re-acquire motor skills mastered before the CVA or copy the actions of others. Motor imaging training is a sort of therapy in which the patient imagines a gesture or movement in order to learn, reinforce, or improve the movement's performance. A study done in South Korea, published in 2015, revealed that Motor imagery training has a good impact on UL performance by refining functional mobility during stroke rehabilitation. The results suggest that motor imagery training is viable and helpful for improving UL function in CVA patients.

Meta-analysis done in Australia in the year 2013, was supportive of Motor imaginary techniques further convincing that Mental imagery can be a possible intervention for stroke patients given that it being, safe cost-effective \& unlimited practice opportunities. Study done in China in 2017, suggested that clinicians should consider the use of MI in addition to treatment currently used to improve upper extremity functions after stroke as no evidence of side effects or harm was noted . RCT done in year 2006 in USA indicated that for patients with chronic, moderate upper limb impairment after CVA, program of CIMT with mental practice only resulted in decrease impairment, with functional enhancement.

Eligibility Criteria:
Inclusion Criteria:

* MCA stroke
* Chronic stroke patients
* Mini-Mental State Examination (MMSE) score \>24 points
* Spasticity grade II and III on Modified Ashworth scale

Exclusion Criteria:

* Severe cognitive disability such as depression, unilateral neglect, seizure, dementia,
* Any MSK disorder including muscle contracture
Role of Oral Steroid Alone Versus Oral Steroid Plus Intratympanic Steroid Injection in Bell's Palsy

intratympanic steroid injection bell's palsy

Role of oral steroid alone versus oral steroid plus intratympanic steroid injection in Bell's palsy

Eligibility Criteria:
Inclusion Criteria:

* Mean Aged 18 years or more.

  * Acute unilateral facial palsy without skin lesions which developed within a 72-hour period and is present for 21 days or less.
  * Moderate to severe facial palsy \[House-Brackmann grade IV or greater\]

Exclusion Criteria:

* Another cause of facial nerve paralysis that is not idiopathic.

  * Otologic disease including otitis media, temporal bone fracture, a previous history of facial nerve palsy in either side, history of otologic surgery, and suspected Ramsay Hunt syndrome.
  * Systemic disease including history of tuberculosis, history of head and neck cancer, other neurological disorders, recent use of ototoxic medications, liver or renal dysfunction, and other illnesses that would contraindicate the use of high-dose steroid therapy.
  * Pregnancy
SpO2 Data Collection in Pediatric Patients Using INVSENSOR00061

This is a prospective, non-randomized data collection study to evaluate the form, fit, and function of INVSENSOR00061.


Eligibility Criteria:
Inclusion Criteria:

* • Subject is a full-term newborn (37 weeks) to 18 months of age.

Exclusion Criteria:

* • Subject has underdeveloped skin.

  * Subject has a skin condition and/or deformity at the planned application site, which would preclude sensor placement and measurements.
  * Subject has an absence or deformities of limbs or severe edema, which would interfere with sensor application or prevent the proper fit of the sensors.
  * Subject is not suitable for the investigation at the discretion of the Investigator.
Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity

Researchers are trying to test the effectiveness and feasibility of a multicomponent lifestyle intervention to support weight loss decreases dyspnea in obese people with chronic lung disease and clinically significant breathlessness.

Patient will be randomized to a 12-week intervention that uses the Weight watchers lifestyle program online, a Garmin Fitness Tracker, blue tooth scale and receive health coaching vs a wait-list control group.

Eligibility Criteria:
Inclusion Criteria

* Age ≥ 18 years.
* BMI \>=35
* Dyspnea MRC class II or greater
* Diagnosis of lung disease
* Signed informed consent

Exclusion Criteria

* BMI \<35
* Pregnancy
* Recent respiratory illness (within the last 6 weeks)
* Recent exacerbation of chronic lung disease (within the last 6 weeks)
* Already participating in a structured diet and/or exercise program
* Medical contraindication to weight loss (cancer)
* Medical contraindication to unsupervised exercise (unstable angina)
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory, LLC) in Subjects With Stable, Mild Asthma


Eligibility Criteria:
Inclusion Criteria:

1. Men or non-pregnant women 18 to 65 years of age.
2. Signed informed consent form that meets all criteria of current Food and Drug Administration (FDA) regulations.
3. Females of childbearing potential must not be pregnant or lactating (as confirmed by a negative urine pregnancy test
4. Ability to use inhalation aerosol correctly.

Exclusion Criteria:

1. Any clinically significant finding on physical exam in the opinion of the Investigator, would compromise subject's safety or data integrity.
2. Employees of the Investigator or research center or their immediate family members.
3. Previous participation in this study.
4. Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor

The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.


Eligibility Criteria:
Inclusion Criteria:

* Provide written informed consent;
* Pregnant women at ≥ 36 weeks 0 days inclusive gestation;
* Women aged 18 years or older;
* Candidate for pharmacologic induction of labor;
* Single, live vertex fetus;
* Baseline modified Bishop score ≤ 4;
* Parity ≤ 3 (parity is defined as one or more births live or dead after 24 weeks gestation);
* Body Mass Index (BMI) ≤ 50 at the time of entry to the study.

Exclusion Criteria:

* Nulliparous women participating in the pharmacokinetic (PK) arm of the study: women with hemoglobin level \< 11.0 grams per deciliter (g/dL) (confirmed within one week of study drug insertion);
* Women in active labor;
* Presence of uterine or cervical scar or uterine abnormality e.g., bicornate uterus. Biopsies, including cone biopsy of the cervix, are permitted;
* Administration of oxytocin or any cervical ripening or labor inducing agents (including mechanical methods) or a tocolytic drug within 7 days prior to enrollment. Magnesium sulfate is permitted if prescribed as treatment for pre-eclampsia or gestational hypertension;
* Severe pre-eclampsia marked by Hemolytic anemia, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, other end-organ affliction or Central Nervous System (CNS) findings other than mild headache;
* Fetal malpresentation;
* Diagnosed fetal abnormalities;
* Any evidence of fetal compromise at baseline (e.g., non-reassuring fetal heart rate pattern or meconium staining);
* Ruptured membranes ≥ 48 hours prior to the start of treatment;
* Suspected chorioamnionitis;
* Fever (oral or aural temperature \> 37.5˚C);
* Any condition in which vaginal delivery is contraindicated e.g., placenta previa or any unexplained genital bleeding at any time after 24 weeks during this pregnancy;
* Known or suspected allergy to misoprostol, other prostaglandins or any of the excipients;
* Any condition urgently requiring delivery;
* Unable to comply with the protocol.
A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions

A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets under fed conditions.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male or female subjects between the ages of 21 and 55 years.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight \> 45 kg (99 lbs).

Exclusion Criteria:

* Any condition possible affecting drug absorption (eg, gastectomy).
* A positive urine drug screen.
Effect of Patient Navigation on Colonoscopy Completion Screening Rate for Colorectal Cancer.

The goal of this randomized controlled trial is to evaluate the effectiveness of patient navigation on colonoscopy completion rates in a population screened for colorectal cancer. The main question\[s\] it aims to answer are:

Are colonoscopy completion rates in colorectal cancer screening increased in navigated (intervention arm) compared with non-navigated (control arm) participants?

Is mental well-being, as measured by HADs and GHQ12 scores, better in the intervention arm compared with the control arm?

Participants in the intervention arm will receive:

* standard clinic instructions for the colonoscopy
* phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure
* a webpage QR code consist of information on visual image on colonoscopy preparation and procedures, layout and map guidance to navigate in the hospital
* a direct line for phone calls to patient navigators for further guidance on overcoming barriers

Participants in the control arm will only receive:

* standard clinic instructions for the colonoscopy
* one phone call from the patient navigator to discuss the colonoscopy procedure


Eligibility Criteria:
Inclusion Criteria:

* Average risk for CRC
* More than 50 years of age
* Capacity for informed consent
* IFOBT positive

Exclusion Criteria:

* Moderate or high risk CRC
* Previous CRC screening
* Symptomatic
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.

PURPOSE: This clinical trial is studying to see if certain genes may be associated with cancer in patients with cancer of the breast, prostate, lung, or colon and siblings of these patients.

OBJECTIVES:

* Gather allele-sharing statistics at approximately 100 candidate loci throughout the human genome most likely to influence genetic risk of cancer.
* Use these allele-sharing statistics to test the interaction of each locus individually with cancer-associated, rare alleles of HRAS1.
* Generalize this approach for one of four cancers (breast, colon, lung, or prostate), using allele-sharing statistics to test the interaction of each locus with every other locus.
* Replicate positive results in a distinct set of sibling pairs with cancer.
* Examine, when loci contributing to risk are detected, the influence of this genetic background on clinical outcomes, such as survival.

OUTLINE: Each patient-sibling pair completes a family history questionnaire about the incidence of cancer in the family. Blood samples are obtained from both the patient and the sibling (and both living parents, if available).

The blood samples are genotyped using approximately 300 micro-satellite markers flanking 100 candidate genes previously implicated in genetic risk for cancer. Certain loci are a priority due to their association with HRAS1: BRCA1 and all known mismatch repair loci; other repair genes, such as ATM; the Bloom's syndrome locus; and the XRCC group. Other genes are also mapped.

Patients do not receive the results of the genetic testing and the results do not influence the type and duration of treatment.

Patients only are followed annually.

PROJECTED ACCRUAL: This study will accrue 1,000 patient-sibling pairs for breast cancer. After 18 months, another 1,000 patient-sibling pairs will be accrued for breast cancer. Therefore, up to 2,000 patient-sibling pairs will be accrued over 5 years. (Feasibility of accruing pairs for lung, colon, and prostate cancer is being assessed.)

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed colon, lung, prostate, or invasive breast cancer

  * No ductal or lobular carcinoma in situ of the breast only
* Patient and natural full sibling must have (or have had) cancer of the same type
* Participants in E-3Y92 not eligible
* Hormone receptor status:

  * Not specified

PATIENT CHARACTERISTICS:

Age:

* Not specified

Menopausal status:

* Not specified

Performance status:

* Not specified

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* Not specified

Radiotherapy

* Not specified

Surgery

* Not specified
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

The study aims to compare tau targeted radiotracers \[18F\]GTP1 and \[18F\]PI-2620 or \[18F\]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).


Eligibility Criteria:
Inclusion Criteria

* Cognitively normal subjects aged 65 to 90 years and prodromal to mild AD subjects aged 50 to 90 years, inclusive at the time of screening.
* Prodromal to moderate AD subjects: Meet the National Institute on Aging - Alzheimer's Association (NIA-AA) core clinical criteria for mild cognitive impairment (MCI) due to AD, probable AD dementia or AD dementia
* Have a Clinical Dementia Rating (CDR) score of 0 (cognitively normal) or 0.5 (prodromal to moderate AD) at screening
* Have an Mini-Mental State Examination (MMSE) score 10-30 inclusive
* Have Aβ PET imaging demonstrating Aβ binding based on qualitative visual read at screening or using an acceptable historical PET scan (cognitively normal subjects will be assessed with Aβ PET at screening but will not be required to demonstrate Aβ binding).
* A brain MRI consistent with normal cognition or that supports a diagnosis of prodromal to moderate AD, with no evidence of other significant neurologic pathology. A previously acquired research MRI within the last 12 months may be used if deemed acceptable by the investigator and no significant clinically relevant changes have occurred since the prior MRI was obtained
* The subject has an appropriate study partner capable of participating in CDR assessment and, if necessary, of accompanying the subject
* For cognitively normal subjects only: History of at least one first degree relative with diagnosis of Alzheimer's disease (self-reported by the potential subject and/or confirmed by the study partner).

Exclusion Criteria

* Current or prior history of any alcohol or drug abuse within the last 2 years
* Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds the effective dose of 50 millisievert (mSv), which would be above the acceptable annual limit established by the US Federal Guidelines
* Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease
* MRI evidence of cerebrovascular disease, infectious disease, space-occupying lesions, normal pressure hydrocephalus, or other central nervous system (CNS) disease
* Implants that have not been certified for MRI or history of claustrophobia in MRI, unless an acceptable previously acquired research MRI is available
Evaluation of a Closed Assisted Reproductive Technology (ART) Station Versus an Open Flow Cabinet

There is not yet a standardized system of human embryonic culture in vitro. In addition, technical improvements continually appear. The investigators recently carried out a study in which it shows that the grouped embryo culture at low oxygen tension (5% O2) in a benchtop incubator shows better success rates than individual culture at atmospheric oxygen tension (20% O2) in a conventional incubator. For these reasons, the investigators have decided to continue this research line to evaluate the efficacy of a new ART station with a closed environment in comparison of an open flow cabinet. This new system keeps a controled environment maintaining a carbon dioxide (CO2) concentration of 6% and a temperature of 37 degrees. A prospective randomized study will be carried out in which the manipulation of the gametes and pre-embryos of the patients will be carried out in open laminar flow cabinets or in a closed station that maintain the CO2 and temperature conditions.


Eligibility Criteria:
Inclusion Criteria:

* Signing a written consent to participate in the study.
* Blastocyst transfer:
* Patients using their own oocytes under 40 years.
* Patients using donated oocytes.

Exclusion Criteria:

* Preimplantation genetic screening patients.
* Severe male factor (spermatozoa of testicular or epididymal origin, patients with cryptozoospermia and patients with retrograde ejaculation)
Characterization of Cleft Lip and Palate Conditions in Guatemala

The purpose of this study is to compare types of and risk factors for cleft lip and palate in a Guatemalan population to a United States population.

Demographic, surgical, and cleft type data from US patients were gathered via chart review of the electronic medical record. Data from Guatemalan patients was gathered orally from patient caregivers in their native language. Consent was also given orally in the caregivers native language. All data was de-identified prior to analysis.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of isolated cleft lip and/or palate
* scheduled for cleft-related surgery at either the Children's Hospital of Philadelphia or Smiles for Guatemala during the previously described time frames

Exclusion Criteria:

* diagnosis of a recognized medical syndrome
* medically complex defined as having major medical problems in three or more organ systems
* diagnosis of isolated midline cleft lip
* diagnosis of Tessier facial cleft
* greater than 18 years of age